MARKET

CTXR

CTXR

Citius Pharmaceuticals Inc
NASDAQ
0.6500
+0.0370
+6.04%
After Hours: 0.6599 +0.0099 +1.52% 19:53 05/13 EDT
OPEN
0.6125
PREV CLOSE
0.6130
HIGH
0.6697
LOW
0.6013
VOLUME
719.14K
TURNOVER
--
52 WEEK HIGH
2.480
52 WEEK LOW
0.5700
MARKET CAP
17.62M
P/E (TTM)
-0.2229
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTXR last week (0504-0508)?
Weekly Report · 3d ago
Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility
TipRanks · 5d ago
Citius Pharma adds $0.9 share conversion option to $3.8 million Citius Oncology note
PUBT · 5d ago
Citius Oncology issues new warrants for 25555556 shares after USD 11.5 million exercise
PUBT · 05/06 00:09
Citius Oncology enters up to $25 million senior secured loan facility with Avenue Capital Group
PUBT · 05/06 00:01
Weekly Report: what happened at CTXR last week (0427-0501)?
Weekly Report · 05/04 09:49
Citius Expands LYMPHIR Access with First European Shipment
TipRanks · 04/29 22:33
Citius Pharma unit Citius Oncology ships first LYMPHIR order to Europe
PUBT · 04/29 21:16
More
About CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.

Webull offers Citius Pharmaceuticals Inc stock information, including NASDAQ: CTXR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTXR stock methods without spending real money on the virtual paper trading platform.